Department of Medical Surgical Science and Translational Medicine, Sant' Andrea Hospital, Sapienza University of Rome, Rome, Italy.
Department of Medical Surgical Science and Translational Medicine, Sant' Andrea Hospital, Sapienza University of Rome, Rome, Italy;
Anticancer Res. 2023 Jun;43(6):2813-2820. doi: 10.21873/anticanres.16450.
BACKGROUND/AIM: Thanks to the promising benefits obtained in terms of quality of life, there has been growing interest in organ-sparing approaches after neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer, mainly represented by transanal local excision and watch-and-wait. The main mandatory criterion is complete lymph nodal response (pN0). However, considering the reduced specificity of current radiological means in identifying one-to-one correspondence between clinical and pathological staging, the problem of underestimating lymph nodal involvement remains unsolved. The aim of this study was to identify the true percentage of patients eligible for conservative surgery and possible predictive factors.
Data for 59 patients with rectal cancer treated with nCRT followed by total mesorectal excision were analyzed. Patients with metastatic tumors and tumors treated with up-front surgery were excluded. Our primary endpoint was the pathological lymph nodal response rate after neoadjuvant chemoradiotherapy. The secondary endpoint was to identify predictive factors for lymph nodal response.
The percentage of patients with pN0 was 62.71%, while in 37.28%, an organ-sparing approach would have not been oncologically correct. Parameters associated with pN0 were lower tumor size (T0-T2) (p=0.013) and lower grading (<G3) (p=0.06). Parameters associated with poorer disease-free survival were pN+ (p=0.019), higher lymph node ratio (p=0.001), and higher stage (p=0.038).
Organ-sparing approaches may be a promising option in patients with extraperitoneal rectal cancerthat respond to nCRT. Nevertheless, it is essential to consider the limit of lymph node metastases to ensure oncological safety and, especially in cases with advanced tumors, total mesorectal excision should be the approach of choice.
背景/目的:新辅助放化疗(nCRT)后,保肛治疗方法(主要包括经肛门局部切除术和观察等待)在局部进展期直肠癌患者中具有提高生活质量的显著优势,因此引起了广泛关注。该方法的主要强制性标准是完全淋巴结反应(pN0)。然而,考虑到当前影像学方法在识别临床分期和病理分期之间一对一对应关系的特异性较低,低估淋巴结受累的问题仍未得到解决。本研究旨在确定有资格进行保肛手术的患者的真实比例和可能的预测因素。
分析了 59 例接受 nCRT 后行全直肠系膜切除术治疗的直肠癌患者的数据。排除了转移性肿瘤和直接手术治疗的患者。我们的主要终点是新辅助放化疗后病理淋巴结反应率。次要终点是确定淋巴结反应的预测因素。
pN0 患者的比例为 62.71%,而在 37.28%的患者中,保肛方法在肿瘤学上是不正确的。与 pN0 相关的参数包括肿瘤较小(T0-T2)(p=0.013)和分级较低(<G3)(p=0.06)。与无病生存相关的参数包括 pN+(p=0.019)、更高的淋巴结比率(p=0.001)和更高的分期(p=0.038)。
在对 nCRT 有反应的腹膜外直肠癌患者中,保肛治疗方法可能是一种有前途的选择。然而,必须考虑到淋巴结转移的局限性,以确保肿瘤学安全性,特别是在晚期肿瘤患者中,全直肠系膜切除术应该是首选方法。